1. Home
  2. ATOM vs MOLN Comparison

ATOM vs MOLN Comparison

Compare ATOM & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Atomera Incorporated

ATOM

Atomera Incorporated

SELL

Current Price

$4.14

Market Cap

157.7M

Sector

Technology

ML Signal

SELL

Logo Molecular Partners AG

MOLN

Molecular Partners AG

BUY

Current Price

$3.81

Market Cap

170.5M

Sector

N/A

ML Signal

BUY

Company Overview

Basic Information
Metric
ATOM
MOLN
Founded
2001
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Semiconductors
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
157.7M
170.5M
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
ATOM
MOLN
Price
$4.14
$3.81
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $10.36
AVG Volume (30 Days)
★ 377.7K
1.7K
Earning Date
10-27-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 4.41
N/A
EPS
N/A
★ N/A
Revenue
★ $62,000.00
N/A
Revenue This Year
$361.54
N/A
Revenue Next Year
$233.33
$450.00
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.89
$3.53
52 Week High
$12.37
$5.36

Technical Indicators

Market Signals
Indicator
ATOM
MOLN
Relative Strength Index (RSI) 45.29 42.29
Support Level $4.16 $3.79
Resistance Level $4.49 $4.39
Average True Range (ATR) 0.22 0.16
MACD 0.05 -0.05
Stochastic Oscillator 35.36 6.19

Price Performance

Historical Comparison
ATOM
MOLN

About ATOM Atomera Incorporated

Atomera Inc is engaged in the business of developing, commercializing, and licensing proprietary processes and technologies for the semiconductor industry. The company's technology, named Mears Silicon Technology, or MST, is a thin film of re-engineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the majority of widely used in the semiconductor industry. The company's silicon technology can be used for applications like Analog, DRAM, logic, processors, and SRAM. Geographically, it generates maximum revenue from North America.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Share on Social Networks: